INTRODUCTION
Type 2 diabetes (T2D) represents a global health epidemic that is predicted to double in prevalence over the next 20 years, causing blindness, amputation, neuropathy, and life-threatening macrovascular complications (Boyle et al., 2010) . The disease is characterized by impaired insulin action in target organs and a failure of insulin secretion to compensate for this defect. Progression of disease correlates closely with decreases in insulin secretion (Fonseca, 2009) , and human genetic studies of both Mendelian and common forms of diabetes have highlighted a central role of beta-cell dysfunction in the inherited basis of T2D (Ingelsson et al., 2010) . Identifying the mechanisms by which beta cells fail in diabetes, and targeting such pathways therapeutically, could prevent the development of the condition and significantly improve its treatment.
Historically, assays of beta-cell function have relied on the ELISA, the gold standard for measuring insulin. This method, while of critical importance to the field, is characterized by multiple liquid-handling steps, limited dynamic range, and high cost (> $2 per sample), making it challenging for use in highthroughput applications. Recently, 384-well insulin assays based on fluorescence resonance energy transfer (FRET) have become commercially available (Degorce, 2006; Bielefeld-Sevigny, 2009 ). While these assays enable larger format experiments, they remain relatively expensive ($0.60-$1.70 per sample), require supernatant transfer steps, and involve plate readers with advanced hardware compatible with these methods (i.e., time-resolved FRET; AlphaLISA laser-based detection). As a consequence, only two small-scale chemical screens of insulin secretion have been published to date, and the size of each (1,280 and 4,691 compounds) limited their ability to detect novel insulinotropic compounds (Wu et al., 2008; Lee et al., 2011) .
Several groups have attempted to circumvent the ELISA using surrogate markers of insulin secretion, by fusing either GFP or luciferase to the end of the insulin propeptide (Pouli et al., 1998; Liu et al., 2007; Suzuki et al., 2011) . While some have been useful for tracking exocytotic events, none have demonstrated correlation with the insulin ELISA. Moreover, the constructs appear to have detrimental effects on cell function, possibly due to protein misfolding. Over 95% of a proinsulin-firefly luciferase fusion protein is retained in the ER, and cells expressing a proinsulinGaussia luciferase construct show less than 3-fold induction of secretion upon maximal glucose stimulation.
A rapid and inexpensive way of tracking insulin secretion would enable the systematic and comprehensive evaluation of genetic and environmental factors contributing to insulin deficiency in diabetes and the search for compounds reversing these defects. Here, we report the design and validation of a luminescent insulin secretion assay created by inserting Gaussia luciferase within the C-peptide portion of the insulin prohormone, flanked by additional prohormone convertase cleavage sites. Upon stimulation with known insulin secretagogues, beta cells expressing this reporter secrete luciferase in close correlation with insulin, under standard conditions as well as upon induction of cellular stress. At a cost of $0.05 per sample, the assay requires > 40-fold less time and expense than the traditional ELISA. Moreover, it performs well in high-throughput applications, and can be used without a supernatant transfer step. Using the reporter, we performed a proof-of-principle, 1,600-compound screen, under both low-and high-glucose conditions, identifying several small molecule modulators of beta-cell secretion. Top-scoring compounds from the highglucose screen were subsequently confirmed to augment glucose-stimulated insulin secretion (GSIS) from cadaveric islets, validating the relevance of the assay to human biology. Moreover, one of the drugs found to decrease secretion in our screen, fenofibrate, was subsequently confirmed to inhibit insulin secretion from human islets, demonstrating the potential of the assay for identifying negative effects of commonly used medications on beta-cell function.
RESULTS

Creating a Luminescent Insulin Secretion Reporter
We reasoned that luciferase could be used to track insulin secretion if properly targeted to the secretory vesicles within the beta cell via the endogenous proinsulin processing pathway, in a manner that preserved the activity of the enzyme. To accomplish this, we constructed a fusion protein in which the sequence of Gaussia luciferase was placed within the C-peptide portion of mouse proinsulin, a fragment that is normally cleaved within the vesicles by pH-sensitive prohormone convertase enzymes and cosecreted with mature insulin during exocytosis (Oyer et al., 1971) . Gaussia luciferase was chosen because it is the smallest and brightest luciferase identified to date (Tannous et al., 2005) . To ensure full activity of the luciferase, a version was used that was codon-optimized for expression in mammalian cells, and we flanked the enzyme with additional cleavage sites for prohormone convertase 2 (PC2), such that no extra amino acids would be present on the ends of the enzyme after processing within the vesicles ( Figure 1A ).
In the absence of a suitable glucose-responsive human betacell line, we created both mouse (MIN6; Miyazaki et al., 1990) and rat (INS-1E; Merglen et al., 2004) beta-cell lines stably expressing the reporter construct. Each line was indistinguishable from its wild-type counterpart in terms of morphology, replication rate, and viability. The luminescent reporter of insulin secretion was validated in both cell lines, with highly similar results between species.
Upon challenging INS-1E cells expressing the reporter with varying concentrations of glucose for 1 hr, secretion of insulin and luciferase were highly correlated (r 2 = 0.99; Figures 1B and   1C ). Similar results were obtained from MIN6 cells ( Figure S1 available online). To confirm that the proinsulin-luciferase fusion protein tracked with insulin and was not retained in the ER, immunohistochemistry was performed on single cells. Confocal imaging revealed nearly complete colocalization of insulin and luciferase within the secretory granules, suggesting that the fusion protein folds properly and enters the natural proinsulinprocessing pathway ( Figures 1D, 1E , and S2). Next, to determine if the reporter could be used to track insulin secretion from human beta cells, dissociated human islets were transduced with a lentiviral expression vector containing the reporter. Upon stimulation of these cells with varying glucose levels, luciferase and insulin were secreted in close correlation ( Figure 1F ). The effect of the fusion construct on beta-cell function and endogenous insulin secretion was then evaluated by comparing the C-peptide response of cells with and without the transgene. No significant difference was found upon stimulation with glucose, suggesting that, unlike other reported fusion proteins, our reporter does not impair normal insulin processing ( Figure 1G ). We further tested the time course of glucose-stimulated secretion in the INS-1E cell line, observing a predominantly monophasic pattern, with the magnitude of secretion increased by the known glucose-dependent insulin secretagogue 3-isobutyl-1-methylxanthine (IBMX; Figure 1H ). To confirm that cells expressing the reporter secrete luciferase via the regulated insulin secretion pathway, we examined the effect of diazoxide, a compound known to hyperpolarize the beta cell and inhibit insulin secretion. As expected, the compound also inhibited luciferase secretion from cells expressing the fusion protein ( Figure 1I ).
Verifying the Reporter with Known Secretagogues
To determine if the fusion construct could reliably report insulin secretion across a broad range of stimuli, we applied a panel of known secretagogues to cells expressing the reporter, including small molecules, metabolites, and hormones known to affect insulin secretion. Luciferase secretion increased as predicted for each treatment (Figure 2A ). The depolarizing agents, potassium chloride and glipizide, triggered insulin secretion even in the absence of glucose, though glucose amplified the amount of secretion in a concentration-dependent manner. In contrast, a glucokinase activator increased secretion primarily in the presence of permissive glucose levels, left-shifting the glucose response curve of the cells, but not affecting their maximal response. The amino acid arginine exhibited a modest glucose-dependent effect on luciferase secretion, as did the incretin hormone glucagon-like peptide-1 (GLP-1). Increasing levels of the secondary messenger cyclic adenosine monophosphate (cAMP) using either IBMX or forskolin led to a profound increase in luciferase secretion at higher glucose levels. Likewise, phorbol 12-myristate 13-acetate (PMA), a compound known to augment insulin secretion through stimulatory effects on protein kinase C, had a large effect on secretion. Luciferase activity remained highly correlated with secreted insulin as measured by ELISA ( Figure 2B ).
The reporter was further evaluated by performing doseresponse studies using two well-studied glucose-dependent insulin secretagogues with distinct mechanisms of action: IBMX and a glucokinase activator. As expected, IBMX increased secretion of luciferase from the cells only in the presence of high glucose ( Figure 2C ). In contrast, the glucokinase activator did not stimulate additional secretion in high glucose, but did augment secretion in low glucose when tested at higher concentrations ( Figure 2D ), consistent with the relative glucose-dependent nature of this class of secretagogue (Rees and Gloyn, 2013) .
Tracking Beta-Cell Function under Stress
The toxic environment of the beta cell has been implicated in the pathogenesis of both forms of diabetes, and therapies that counteract this detrimental milieu may reverse the course of disease (Wajchenberg, 2007) . To evaluate the luminescent reporter in this setting, beta-cell dysfunction was induced using three established negative mediators: inflammatory cytokines, saturated fatty acids, and ER stress-inducing agents.
Cells expressing the luminescent reporter were treated for 24 hr with a cocktail of cytokines known to be elevated in T2D (Donath et al., 2010) , including interleukin-1-beta (IL1b), tumor necrosis factor-alpha (TNFa), and interferon-gamma (IFN-g), prior to stimulating luciferase secretion with varying glucose concentrations. As expected, luciferase secretion at physiologic and high-glucose levels decreased in proportion to the concentration of cytokines applied to the cells ( Figure 2E ). Figure S2 . (F) Correlation between insulin concentration and luciferase activity of dissociated human pancreatic islets expressing the reporter, treated with 2.8 mM, 5.6 mM, 11.1 mM, and 16.7 mM glucose. (G) Secretion of endogenous C-peptide from wild-type and reporter-containing INS-1E cells; data represent mean ± SD (n = 8).
(H) Time course of glucose-stimulated insulin secretion in INS-1E cells in the presence and absence of known insulin secretagogue IBMX (100 mM). Time zero value corresponds to preincubation in 2.8 mM glucose for 5 min, whereas all subsequent time points correspond to incubation in 16.7 mM glucose; data represent mean ± SD (n = 12). (I) Effect of diazoxide on luciferase secretion from INS-1E cells, in both basal and glucose-stimulated states; data represent mean ± SD (n = 8).
Next, lipotoxicity was induced in the reporter cell line using the saturated fatty acid palmitate. Cells were pretreated with a low dose of palmitate for 24 hr to induce lipotoxicity, as chronic exposure to free fatty acids has been implicated in impaired insulin secretion (Hoppa et al., 2009) . Upon stimulation of the cells, luciferase secretion was slightly increased at low-glucose levels and profoundly decreased at higher glucose levels ( Figure 2F ), consistent with published reports (Elks, 1993) .
Finally, the effect of ER stress on luciferase release was tested using thapsigargin, a known inhibitor of the sarcoplasmic and ER calcium channel (SERCA; Lytton et al., 1991) . After 8 hr of treatment with this compound, glucose-stimulated luciferase secretion dropped substantially and in a dose-dependent manner ( Figure 2G ).
Adapting the Reporter to High-Throughput Screening Applications
To enable large-scale chemical and genetic experiments on insulin secretion, the luminescence assay was adapted to 384-well and 1,536-well formats, using a streamlined approach that limited liquid handling steps by performing the assay on cells in suspension. Though secretion from cells in suspension is less than from adherent cells ( Figure S3 ), rodent beta-cell lines respond reproducibly to stimuli in this format, enabling glucose Data represent mean ± SD (n = 4). (E) 24 hr pretreatment with cytokine cocktail containing interleukin-1-beta (13 = 10 ng/ml), tumor necrosis factor-alpha (13 = 25 ng/ml), interferon-alpha (13 = 50 ng/ml). (F) 24 hr pretreatment with the saturated fatty acid palmitate at various concentrations. (G) 8 hr pretreatment with thapsigargin, a known inducer of ER stress, at various concentrations. starvation and wash steps to be performed prior to plating cells, which greatly reduces well-to-well variability. In addition, as more cells can be plated per well in suspension, the signal intensity per well is increased significantly.
In this format, secreted luciferase can be measured either by directly adding the substrate coelenterazine to each well in a homogenous manner, or by transferring the supernatant into an empty plate before adding coelenterazine. The transfer step decreases the background signal, yet the assay still performs well without this step, with ample separation of positive and negative controls. For comparison, the Z 0 factor of the assay (Zhang et al., 1999 ) is > 0.6 when performed in 384-well format with a transfer step, > 0.5 in 384-well format without a transfer step, and > 0.35 in 1,536-well format without a transfer step, using IBMX as the positive control and a glucose concentration of 11.1 mM.
Performing a Pilot Chemical Screen in Low Glucose
After establishing the suitability of the luminescent reporter for high-throughput applications, we performed a pilot small molecule screen in INS-1E cells using a collection of 1,600 known bioactive compounds and natural products, using IBMX and potassium chloride as positive controls. Each compound was first tested in relatively low glucose (2.8 mM) in duplicate, with high reproducibility (r 2 = 0.80), and clear separation of the positive and negative controls ( Figure 3A ). When ranked by mean Z score, approximately 300 compounds increased secretion of luciferase compared to DMSO controls (Table S1 , top). Of these, 48 had a greater Z score than IBMX, and one had a greater Z score than potassium chloride. Several classes of compounds were enriched among the top-scoring 100 small molecules, including the following: anticholinergics/first-generation antihistamines, sodium channel blockers, and prostaglandin antagonists ( Figure 3B , in red at top). In addition, all ten of the sulfonylureas present in the library scored within the top 55 compounds, with most falling within the top 25 (Table 1) . Numerous small molecules used clinically for conditions other than diabetes and without known links to beta-cell function also scored highly.
At the other end of the spectrum, 130 compounds decreased secretion of luciferase compared to DMSO controls (Table S1 , bottom). Classes of small molecules enriched in the bottom-scoring (B) Analysis by class of the 100 top-scoring (red) and 100 bottom-scoring (blue) compounds in the screen, based on reported mechanisms. Number of compounds in each class is shown. a-AR, alpha-adrenergic receptor; b-AR, beta-adrenergic receptor; Na, sodium; K, potassium; Ca, calcium; SSRI, selective serotonin reuptake inhibitor; cAMP, cyclic adenosine monophosphate; HMGCR, 3-hydroxy-3-methyl-glutaryl-CoA reductase; SERM, selective estrogen receptor modulator. See also Figure S3 for comparison of secretion from suspension versus adherent INS-1E cells.
100 compounds included some expected agents: antifungals/ antibacterial agents, antidopaminergics/anticholinergics, calcium channel blockers, alpha-adrenergic receptor agonists, and antiparasitic mitochondrial toxins ( Figure 3B , in blue at bottom). Progestin analogs and selective estrogen receptor modulators (SERMs) also inhibited luciferase secretion at this relatively low glucose, as did PPAR-alpha agonists (fibrates) and several dopaminergic agonists.
Repeating Pilot Chemical Screen in High Glucose
To determine if our luminescent assay could be useful for identifying insulin secretagogues that augment insulin release in the setting of hyperglycemia, as required for a treatment for diabetes, we repeated the compound screen in INS-1E cells using a supraphysiologic glucose concentration (8.3 mM), three times higher than the initial screen. As expected, the baseline secretion of luciferase in this assay was increased at this higher glucose level. Similar to the low-glucose setting, high reproducibility was observed between replicates (r 2 = 0.90), with clear separation of positive and negative controls ( Figure 4A ).
In contrast to the original screen in low glucose, the screen in high glucose identified few compounds that increased secretion of luciferase above baseline. When ranked by mean Z score, only 30 compounds increased luciferase secretion compared to DMSO controls, and none scored higher than the positive control, IBMX (Table S2 , top). The classes of compounds enriched among these top-scoring small molecules were largely distinct from those identified in the low-glucose screen, including the following: cAMP-inducing agents, GABAergic agonists, ion channel modulators, prostaglandin antagonists, and serotonergic antagonists ( Figure 4B , in red at top). Two guanosine analogs also scored highly in the screen, as did one cholinergic agonist (Table 1) . Sulfonylureas were notably absent from the top-ranked compounds in this highglucose screen.
In the high-glucose assay, considerably more compounds decreased secretion of luciferase, with 514 small molecules scoring less than the lowest DMSO control (Table S2 , bottom). The classes of compounds enriched at this end of the spectrum were largely similar to the low-glucose screen, with the 100 bottom-scoring compounds including the following: anticholinergics/antidopaminergics, antifungals/antibacterial agents, calcium channel blockers, ion channel modulators, antiparasitic mitochondrial toxins, and alpha-2 adrenergic receptor agonists ( Figure 4B , in blue at bottom). In addition, several commonly prescribed medications appeared to inhibit glucose-stimulated luciferase secretion, including several angiotensin-converting enzyme (ACE) inhibitors, the PPAR-a agonist fenofibrate, the PPAR-g agonist pioglitazone, SERMs, progestogens, thyroid hormones, and SSRIs. To determine if the findings from the high-throughput assays performed in rat INS-1E cells were specific to this cell line or species, we repeated both the low-and high-glucose screens using mouse MIN6 cells expressing the luminescent reporter. A high degree of overlap was observed between the compounds and related drug classes impacting luciferase secretion ( Figure S4 ).
Validating Compounds on Human Islets
To determine if the secretagogues observed in the rodent cell lines were relevant to human biology, we next tested top-scoring small molecules from our high-glucose screen for effects on insulin secretion in human pancreatic islets. To enable a reproducible assessment of compound activity across multiple islets, human islets were gently dissociated and seeded in 96-well format on extracellular matrix (ECM)-coated plates (Walpita et al., 2012) , achieving a uniform distribution of beta cells across the plate (Figure S5) . The cells remained firmly attached throughout the subsequent wash steps, stimulations, and supernatant harvesting, enabling us to evaluate compounds in parallel with minimal well-to-well variability in beta cell number.
Applying this approach, seven compounds identified in the highglucose screen as increasing luciferase secretion were tested in dissociated human islets: milrinone, forskolin (equivalent to colforsin), anagrelide, ornidazole, cilostazol, pranoprofen, and benoxinate. Compounds were selected that demonstrated a range of responses in our primary screen, including top hits as well as relatively lower-scoring compounds, to enable an assessment of the sensitivity of the assay in identifying human insulinotropics of various potencies. To evaluate relative glucose dependence, each compound was tested at three glucose levels, 1.67 mM (low), 5.6 mM (normal), and 16.7 mM (high), using dissociated islets from each of four nondiabetic cadaveric donors (Table S5 ). Figure 3 , plus: GABA, gamma-aminobutyric acid; ACE, angiotensin-converting enzyme; a1-AR, alpha-1-adrenergic receptor; a2-AR, alpha-2-adrenergic receptor. See also Figure S4 for comparison of high-throughput screening results in INS-1E and MIN6 cells.
All seven compounds were found to consistently increase secretion of insulin from human beta cells ( Figure 5 ) in largely the same order of effect as seen in the primary screen in INS-1E cells ( Figure S6 ). While the effect of each compound was potentiated by glucose, none of the compounds were strictly glucose dependent at the relatively high concentrations used in the assay. Milrinone, a phosphodiesterase inhibitor (PDEI) with known links to beta-cell function (Parker et al., 1997) , increased insulin secretion more than the other compounds. Forskolin, an activator of adenylyl cyclase, increased secretion in all glucose levels tested. Anagrelide, a PDEI used clinically for essential thrombocytosis, was nearly as effective as forskolin in inducing secretion of insulin at high glucose, but produced less of an effect at low glucose. The remaining compounds, including an antiprotozoal agent (ornidazole), another PDEI (cilostazol), an NSAID (pranoprofen), and a sodium channel antagonist (benoxinate), also augmented insulin secretion in a glucose-potentiated manner.
Investigating the Inhibitory Effect of Fenofibrate on Insulin Secretion
One of the compounds identified in our high-glucose screen that strongly inhibited luciferase secretion, the PPAR-a agonist fenofibrate, is of particular interest because of its widespread clinical use in patients with the metabolic syndrome. To further evaluate the effect of this compound on beta-cell function, we tested it in dose on the INS-1E reporter cell line, across varying glucose concentrations ( Figure 6A ). The compound dramatically inhibited secretion, in a dose-dependent manner, with more pronounced effects at concentrations approaching its EC 50 (18 mM in rodent cells). To determine if this effect was relevant to human beta cells, we next tested the compound on dissociated human islets, across varying glucose concentrations, and at concentrations up to its EC 50 (50 mM in human cells). We observed robust inhibition of GSIS, again in a dose-dependent manner, across multiple independent pancreatic islet donors ( Figures 6B and 6C) .
Next, to determine if the compound was blocking secretion by acting proximal or distal to the depolarization of the beta cell, we tested its effect on KCl-mediated luciferase secretion from the INS-1E reporter cells. Similar to somatostatin, an established inhibitor of insulin secretion with multiple effects in the beta cell (Hsu et al., 1991) , fenofibrate severely inhibited secretion of luciferase under maximal KCl-mediated stimulation ( Figure 6D ), implying the presence of an effect late in the exocytotic pathway.
Cells treated with fenofibrate during these assays had no obvious morphologic changes, but to more thoroughly evaluate if the compound was toxic to beta cells, we measured the cellular ATP content of fenofibrate-treated INS-1E cells using the CellTiter-Glo reagent ( Figure 6E ). No significant change in ATP Seven insulinotropic compounds identified as increasing luciferase secretion from INS-1E cells in the high-glucose screen were tested for effects on insulin secretion from dissociated human islets in the context of three glucose concentrations (1.67 mM, 5.6 mM, 16.7 mM); data represent mean ± SD (n = 4). Compounds are ranked by their effect in 16.7 mM glucose, averaged across donors. (A)-(D) represent four independent, nondiabetic islet donors. See also Figure S5 , demonstrating the homogeneous distribution of dissociated human islets used for compound testing; Figure S6 , showing the correlation between compound rank in the INS-1E screen and in human islet experiments; and Table S5 , summarizing the human islet donor information.
content was observed at concentrations up to 50 mM. In contrast, when we measured cAMP levels in cells treated with fenofibrate, we saw a dramatic decrease in this key secondary messenger, greater than the effect of somatostatin ( Figure 6F ). This effect is likely independent of the compound's agonism of PPAR-a, as other compounds in the same class, including gemfibrozil and 9-oxo-10(E),12(E)-octodecadienoic acid, had no effect on insulin secretion (data not shown).
DISCUSSION
Here we describe the creation, validation, and application of a luminescent insulin secretion reporter that facilitates large-scale assays of beta-cell function. The assay takes advantage of the endogenous proinsulin-processing pathway to target Gaussia luciferase to the secretory vesicles within the beta cell. In contrast to the insulin ELISA, the luminescent reporter is fast, inexpensive, and amenable to high-throughput applications in a homogeneous format. In addition to detecting insulin secretagogues, the reporter provides a rapid and straightforward readout of beta-cell dysfunction. As such, it may enable the discovery of compounds or genetic factors protecting against these insults, helping to shed light on the molecular mechanisms by which insulin secretion declines in diabetes.
We demonstrated the utility of the assay by performing pilot screens of 1,600 bioactive compounds and natural products, Figure 6 . Fenofibrate Decreases Glucose-Stimulated Luciferase Secretion, Insulin Secretion, and cAMP Levels in a Dose-Dependent Manner without Affecting Cellular ATP Levels (A) Fenofibrate inhibits glucose-stimulated luciferase secretion from INS-1E cells in a dose-dependent manner. The effect of the compound was tested in the context of four glucose concentrations (2.8 mM, 5.6 mM, 11.1 mM, 16.7 mM); data represent mean ± SD (n = 4). (B and C) Fenofibrate inhibits glucose-stimulated insulin secretion from dissociated human pancreatic islets in a dose-dependent manner; data represent mean ± SD (n = 4). Each plot shows data from an independent, nondiabetic islet donor. (D) Fenofibrate decreases KCl-stimulated luciferase secretion from INS-1E cells, comparable to somatostatin, a known inhibitor of KCl-stimulated insulin secretion. Data represent mean ± SD (n = 8; two-tailed paired Student's t test in relation to DMSO; * < 10 À5 , ** < 10 À8 ).
(E) Fenofibrate has no effect on cellular ATP in INS-1E cells, as measured using the CellTiter-Glo assay after 1 hr incubation with varying concentrations of the compound. Data represent mean ± SD (n = 8).
(F) Fenofibrate decreases cAMP levels in a dose-dependent manner, in INS-1E cells stimulated with forskolin (1 mM) and IBMX (500 mM), similar to somatostatin. Data represent mean ± SD (n = 4; two-tailed paired Student's t test in relation to DMSO; * < 0.002). See also Table S5 , summarizing the human islet donor information.
in both low and high glucose, and in both rat INS-1E and mouse MIN6 beta-cell lines. While these screens were limited to known bioactives, and thus not designed to discover novel small molecules with activity on beta cells, they may nonetheless help to identify pathways of relevance to human beta-cell function. Indeed, in each glucose level tested, several classes of compounds emerged as augmenting or inhibiting luciferase release, many without prior links to insulin secretion. Numerous compounds increased insulin secretion in the low-glucose screen, whereas very few increased secretion in the more physiologically relevant high-glucose screen, likely a reflection of the distinct mechanisms by which secretion is enhanced in each setting. In low glucose, beta cells are in a polarized resting state, and compounds that shift the membrane potential toward depolarization increase secretion, as suggested by the strong effects of sulfonylureas and sodium channel modulators. In high glucose, however, the beta cells are already depolarized, so compounds that trigger depolarization have minimal additional impact on secretion. In this setting, compounds that augment the amplifying pathway of insulin secretion have more prominent effects, such as cAMP-inducing agents (Almahariq et al., 2014) , GABAergic agonists (Bansal et al., 2011) , and 5-HT 1A serotonin receptor antagonists (Uvnä s- Moberg et al., 1996) . Several intriguing classes of compounds emerged as increasing luciferase secretion, including the following: (in low glucose) anticholinergics/first-generation antihistamines, NSAIDs, and statins; (in high glucose) COX-2 inhibitors, angiotensin receptor blockers (ARBs), and guanosine analogs. Supporting the plausibility of these findings, the M2 and M4 muscarinic receptors (Miguel et al., 2002) , as well as certain prostaglandin receptors (Fujita et al., 2007; Kimple et al., 2013) , have been reported to negatively regulate insulin secretion. Likewise, statins may increase insulin secretion in low-glucose conditions (Ishikawa et al., 2006) , and ARBs improve GSIS in human subjects, reducing the progression to diabetes in subjects with impaired glucose metabolism (van der Zijl et al., 2011) . Guanosine analogs may increase the amount of guanosine triphosphate in beta cells, which can directly stimulate insulin secretion (Wollheim and Maechler, 2002) .
Our screens also identified classes of compounds that decreased luciferase secretion, including some common medications that have been implicated previously in inhibiting insulin release: SERMs (Le May et al., 2006) , progestogens (Shao et al., 2004) , SSRIs (Isaac et al., 2013) , and the PPAR-gamma agonist pioglitazone (Lamontagne et al., 2009) . The PPAR-a agonist fenofibrate, not previously known to affect beta-cell function, was found to robustly block glucose-mediated stimulation of secretion in both rodent and human beta cell models in a dose-dependent manner. Prior reports of fenofibrate's effects on beta cells are conflicting, with one group describing a stimulatory effect on hamster insulinoma cells (Shimomura et al., 2004) and another group demonstrating an inhibitory effect in longterm cultures of mouse islets . Our results show that the drug acutely decreases insulin secretion at clinically relevant concentrations, possibly through an inhibitory effect on cAMP, and likely independent of its agonism of PPAR-a.
While a number of compounds identified as agonists and antagonists of luciferase secretion in our screen are in clinical use, few have been reported to affect insulin or glucose levels. Possible explanations for this discrepancy include the following:
(1) the relatively high concentrations of compounds used in this screen relative to their expected serum levels in patients; (2) the effect of in vivo drug metabolism on compound activity; (3) a limitation of using rodent beta-cell lines and/or isolated cadaveric islets to model complex human biology; (4) as-yet unappreciated side effects of these medications. The luminescent reporter may help to identify effects of medications on beta-cell function that have not been recognized clinically, by creating hypotheses that can be further evaluated using the appropriate clinical and translational research tools (e.g., electronic medical record databases, animal models).
While advantageous for the applications described, the luminescent insulin secretion assay has several limitations. First, it does not detect changes in expression of insulin, but rather, like the ELISA, monitors hormone secretion. Perturbations affecting insulin promoter activity alone, such as those caused by certain beta cell toxins, may not be identified using the reporter. Second, the assay relies on the expression of our fusion construct in an appropriate beta-cell model. We have used well-validated rodent beta-cell lines as surrogates for the human beta cell, yet important differences in beta-cell function exist between species, as well as between transformed cell lines and primary cells. All results must therefore be confirmed using primary human islets and an insulin immunoassay, as we have done. Notably, the reporter appears to function well in human beta cells, and continued efforts to generate functional human beta-cell lines offer the potential to deploy our reporter in an even more relevant biological context. Third, the expression of the luminescent reporter itself may impact aspects of beta-cell function in subtle ways that could influence experimental results. Though we confirmed that C-peptide secretion from reporter-containing INS-1E cells is similar to that from wild-type cells, we cannot rule out an effect of the constitutive expression of the fusion protein on other functional readouts, such as the ER stress response.
In summary, we have shown that a fusion protein in which Gaussia luciferase is placed within the C-peptide portion of the insulin prohormone can be used to create a high-throughput luminescent assay of beta-cell function, enabling large-scale experiments that have historically been impractical. Application of this assay to larger, unbiased compound screens may help to characterize the molecular mechanisms governing insulin release, as well as to identify therapeutic leads for preserving and improving beta-cell function in diabetes. Additional reporters based on prohormone-luciferase fusion proteins may also prove useful to monitor the secretion of other peptide hormones relevant to metabolic disease for which immunoassays are currently limiting.
EXPERIMENTAL PROCEDURES
Cell Culture MIN6 cells were a gift from Dr. Jun-ichi Miyazaki (Osaka University) and were maintained in DMEM with 4.5 g/l glucose, supplemented with 10% heat-inactivated fetal bovine serum and 55 mM beta-mercaptoethanol (Sigma). INS-1E cells were a gift from Dr. Claes Wollheim and Dr. Pierre Maechler (University of Geneva) and were maintained in RPMI with 2 g/l glucose, supplemented with 10% heat-inactivated fetal bovine serum, 1 mM sodium pyruvate, 2 mM L-glutamine, 10 mM HEPES, and 55 mM b-mercaptoethanol (Invitrogen). Cells were grown on tissue culture-treated plastic and dissociated with TrypLE (Invitrogen).
Proinsulin-Luciferase Construct
The proinsulin-luciferase fusion construct was created by Gibson Assembly in the pUC19 vector using two gBlocks (Integrated DNA Technologies) encoding the protein and Gibson Assembly Master Mix (New England Biolabs). The proinsulin-luciferase fusion construct was subsequently PCR-amplified with primers to add attB1 and attB2 sites, inserted by BP Clonase II into the Gateway Entry vector pDONR223 (Invitrogen), and then shuttled by LR Clonase II into the Gateway Destination vector pLX304 (Yang et al., 2011 ; Addgene plasmid 25890).
Lentiviral Infection
Lentivirus expressing each prohormone-luciferase fusion protein was produced using a second-generation viral packaging system and used to infect rodent beta-cell lines or human islets, as described in the Supplemental Experimental Procedures.
Immunofluorescence
Cultures were fixed, permeabilized, and stained with antibodies to Gaussia luciferase (NanoLight) and insulin (Sigma), as described in the Supplemental Experimental Procedures. Cultures were then incubated in secondary antibodies (Alexa Fluor-conjugated anti-rabbit and anti-guinea pig; Invitrogen), and images were acquired by confocal microscope.
Secretion Assays
For standard secretion assays, MIN6 and INS-1E cells were plated in 96-well format, preincubated for 1 hr in Krebs Ringer Buffer (KRB) with 2.8 mM glucose, and then stimulated for 1 hr in fresh KRB containing varying amounts of glucose and compounds, as described in the Supplemental Experimental Procedures. Insulin or C-peptide concentration was determined using an ELISA (Mercodia), following the manufacturer's protocol. Luciferase activity was determined from the same samples by adding the coelenterazine substrate (NanoLight) to the supernatant to a final concentration of 10 mM and reading on a standard plate reader (BioTek).
Inducing Beta-Cell Dysfunction INS-1E cells were treated with cytokines, palmitate, or the ER stress-inducing agent thapsigargin to induce cellular dysfunction. For cytokine treatment, we used a mixture that included 10 ng/ml of IL-1b, 50 ng/ml of IFN-g, and 25 ng/ml of TNF-a (R&D Systems), referred to as the ''1X'' concentration, dissolved in standard INS-1E growth medium. For palmitate treatment, we dissolved the fatty acid (Sigma) to 50 mM in 90% ethanol at 60 C for several hours, and then diluted this stock in RPMI containing 1% BSA, with all samples receiving the same amount of BSA. For thapsigargin treatment, we dissolved the compound (Sigma) to 1 mM in DMSO and then diluted this stock solution in RPMI containing 1% BSA. Cells were incubated for 24 hr in cytokines and palmitate, or 8 hr in thapsigargin, prior to performing the GSIS assay.
Small Molecule Screens MIN6 and INS-1E cells were expanded to 80% confluence in their respective growth media, washed once in PBS, and preincubated for 1 hr at 37 C in KRB with 2.8 mM glucose. Cells were then dissociated, spun at 300 3 g for 2 min, resuspended in fresh KRB without glucose, and filtered through 40 mm mesh (Becton Dickinson). Next, the cells were counted and diluted in KRB to 1310 6 cells per ml, and glucose was added as required for each experiment.
Cells were then seeded in 384-well format, 3310 4 cells in 30 ml per well, using a Multidrop Combi device (Thermo Scientific). Compounds from the Pharmakon 1,600 Collection (MicroSource Discovery Systems) were pinned into each well using a Vario robot (CyBio) to a final concentration of 30 mM, and the plates were then incubated for 2 hr at 37 C. For assays involving a transfer step, the plates were then centrifuged at 300 3 g for 2 min, and 20 ml of supernatant was transferred to a new 384-well plate. Coelenterazine substrate was then added to a final concentration of 10 mM, and luciferase activity was determined using a standard plate reader (BioTek).
Fenofibrate Investigation
Fenofibrate, gemfibrozil, and 9-oxo-10(E),12(E)-octodecadienoic acid (Cayman Chemical) were resuspended in DMSO, as were forskolin and IBMX (Sigma). Somatostatin-14 (Sigma) was resuspended in sterile water. CellTiter-Glo (Promega) and the cAMP Dynamic-2 HTRF assay (Cisbio) were used according to the manufacturers' instructions. Luciferase secretion and CellTiter-Glo experiments were performed using a 1 hr incubation with compound, whereas the cAMP assay was performed using a 30 min incubation. Secretion experiments were run in KRB buffer; all other experiments were run in standard INS-1E medium.
Statistical Analysis
For the high-throughput screens, a row-based correction factor was applied to all luciferase readings to adjust for logarithmic signal decay, and then a score similar to the statistical Z score for each test compound was calculated, as described in the Supplemental Experimental Procedures.
Human Islet Cell Culture Human islets were obtained through the Integrated Islet Distribution Program (http://iidp.coh.org) and from Prodo Labs (Table S5 ). Islets were maintained and dissociated in 96-well format as described (Walpita et al., 2012) . To test compounds for their effects on insulin secretion, the dissociated islets were washed gently in KRB and preincubated for 1 hr at 37 C in KRB with 2.8 mM glucose. The cells were then washed twice with zero-glucose KRB and placed in 100 ml of fresh KRB with varied glucose concentrations plus compounds. After a 1 hr incubation at 37 C, the supernatant was removed, and insulin concentration was measured by ELISA (Mercodia) according to the manufacturer's instructions. Figures 5 and 6 ). The relative ranking of insulinotropic compounds in the high glucose screen was largely preserved in the human islet experiments, with the exception of benoxinate, a compound with minimal activity in human islets at the concentration tested. 
SUPPLEMENTAL FIGURE LEGENDS
SUPPLEMENTAL TABLE LEGENDS
Lentiviral infection
Lentivirus expressing each prohormone-luciferase fusion protein was produced using a second-generation viral packaging system. Briefly, 2 µg of pLX304 expression plasmid containing the fusion construct, 1.8 µg of psPAX2 packaging plasmid (courtesy of Didier Trono; Addgene plasmid 12260), 200 ng of pMD2.G envelope plasmid (courtesy of Didier Trono; Addgene plasmid 12259) and 12 µL TransIT-LT1 (Mirus Bio) were used to transfect a 10 cm dish of HEK293T packaging cells (American Type Culture Collection). Virus was pooled from harvests at 48 and 72 hours and passed through 0.2 µm cellulose acetate filters (VWR) prior to use. MIN6 cells, INS-1E cells, and dissociated human islets were plated in their respective growth media with the addition of 8 µg/mL polybrene (Sigma). Virus was then added and the cells were spun at 800 x g for 1 hour at 30 °C. After 24 hours in the presence of virus, the cells were placed in fresh growth media. Rodent beta-cell lines were treated with 5 µg/mL blasticidin (Invitrogen) for one week to select for infected cells, and then assessed for luciferase localization and secretion. Assays on infected dissociated human islets were performed on unselected cells three days after infection.
Immunofluorescence
Cultures were fixed for 15 minutes at room temperature using 3% paraformaldehyde and washed twice with phosphate-buffer saline (PBS). Cells were permeabilized for 20 minutes at room temperature in PBS containing 0.1% saponin and blocked overnight at 4°C with 2% bovine serum albumin (BSA) in PBS. Primary antibodies to Gaussia luciferase (Nanolight) and insulin (Sigma) were diluted 1:1000 in antibody dilution buffer (ADB; 1% BSA in PBS) and incubated overnight at 4°C, followed by three washes in ADB.
Cultures were then incubated in secondary antibodies (Alexa Fluor-conjugated anti-rabbit and anti-guinea pig; Invitrogen) diluted 1:1000 in ADB for 1 hour at room temperature, followed by five washes with PBS. Images were acquired using an Ultraview spinning disc confocal microscope with Volocity acquisition software (PerkinElmer).
Secretion assays
For standard secretion assays, MIN6 and INS-1E cells were plated in 96-well format at a density of 4x10 4 cells per well in 100 µL of their respective growth media and incubated overnight at 37 °C in 5% CO 2 to allow attachment. Cells were washed once with PBS and incubated for 1 hour at 37 °C in sterile, 0.45 µm-filtered Krebs Ringer Buffer (KRB) containing 138 mM NaCl, 5.4 mM KCl, 2.6 mM MgCl 2 , 2.6 mM CaCl 2 , 5 mM NaHCO3, 10 mM HEPES and 5 g/L bovine serum albumin (Sigma), with 2.8 mM glucose. The cells were then washed in KRB once and stimulated for 1 hour in 100 µL of fresh KRB containing varying amounts of glucose and compounds. For the time course study, after incubating the cells for one hour in 2.8 mM glucose KRB, the buffer was changed every 5 minutes to fresh, warm (37 °C) KRB containing either 2.8 mM glucose (for the first time point) or 16.7 mM glucose (for all subsequent time points).
Statistical analysis
For the high-throughput screens, a score similar to the statistical Z-score for each test compound was calculated using the formula:
where is the log-transformed, signal decay-adjusted luciferase signal from a compound-treated well, is the mean of the logtransformed, signal decay-adjusted luciferase signals from the DMSO-treated wells on the same plate, and is the standard deviation of the log-transformed, signal decay-adjusted luciferase signals of the DMSO-treated wells across all plates (to allow for cross-plate comparison of compounds). Prior to calculating the score, a row-based correction factor was applied to all luciferase readings, to adjust for the rapid signal decay occurring during the course of each 384-well plate read. The signal decay was modeled as a logarithmic function (Microsoft Excel) and then used to adjust each well's luciferase reading based on the corresponding row within the plate.
